Karyopharm Therapeutics reported $302.89M in Debt for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
Amgen AMGN:US USD 38.94B 241M
AstraZeneca AZN:LN USD 29.3B 229M
Astrazeneca AZN:US USD 29.3B 229M
Avrobio Inc AVRO:US USD 15.2M 101K
Biocryst Pharmaceuticals BCRX:US USD 713.65M 91.47M
Bristol Myers Squibb BMY:US USD 39.32B 222M
GlaxoSmithKline GSK:LN GBP 20.99B 1.13B
Karyopharm Therapeutics KPTI:US USD 302.89M 201K
Novartis NOVN:VX USD 27.91B 530M
Novartis NVS:US USD 27.91B 530M
Regeneron Pharmaceuticals REGN:US USD 2.7B 300K
Roche Holding ROG:VX 27.75B 3.45B
Takeda 4502:JP JPY 4.29T 449.74B
Tg Therapeutics TGTX:US USD 70.04M 1.09M